Adriamycin/cyclophosphamide and adriamycin/melphalan in advanced L1210 leukaemia.
Adriamycin and cyclophosphamide are active agents in human and experimental tumours. Using the L1210 murine leukaemia, their effectiveness alone and in combination was studied. The combination is highly synergistic in this tumour, resulting in a greater than 50% survival rate when the agents used alone at optimal doses are not curative. DNA synthesis by tumour cells is substantially inhibited and the total ascitic population much reduced. In contrast, DNA synthesis in sensitive host tissues is less disturbed. There is no major difference in the pharmacology of the agents whether given alone or in combination. In very advanced disease the combination is no better than treatment with cyclophosphamide alone. The combination of adriamycin and melphalan in L1210 leukaemia also produces superior results to those obtained using either drug alone at its optimal dosage.
D000818:Animals; D001202:Ascitic Fluid / Q000166:cytology / Q000378:metabolism; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004273:DNA, Neoplasm / Q000096:biosynthesis; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000378:metabolism / Q000627:therapeutic use*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D007939:Leukemia L1210 / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality; D008099:Liver / Q000378:metabolism; D008297:Male; D008558:Melphalan / Q000627:therapeutic use*; D051379:Mice
D004273:DNA, Neoplasm; D004317:Doxorubicin; D003520:Cyclophosphamide; D008558:Melphalan